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DEMONSTRASI KEHADIRAN PROTEIN MEMBRAN LUAR YANG 
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ABSTRAK 
 
Acinetobacter baumannii dikenali sebagai bakteria penyebab penyakit nosokomial 
dan kebanyakannya adalah rintang terhadap pelbagai antibiotik. Ianya juga 
dikenalpasti sebagai penyebab utama kepada morbiditi dan kematian di hospital 
terutamanya bagi pesakit yang kurang imuniti terhadap penyakit. Diagnosis awal 
bagi jangkitan yang disebabkan oleh A. baumannii adalah strategi penting untuk 
mengawal jangkitan nosokomial yang disebabkan oleh bakteria ini. Pengenalpastian 
bakteria ini pada masa kini adalah dengan menggunakan kaedah pengkulturan 
konvensional dan ujian biokimia yang mengambil masa lebih kurang 2 hingga 7 hari. 
Oleh sebab itu, ujian yang cepat, sensitif, spesifik dan murah diperlukan untuk 
pengurusan yang cepat terhadap jangkitan nosokomial ini. 
 
Pembangunan ujian yang spesifik dan sensitif memerlukan biomarker yang tidak 
bertindakbalas silang dengan bakteria lain dan spesifik hanya untuk A. baumannii. 
Oleh itu, tujuan kajian ini dilakukan adalah untuk mengenalpasti kehadiran protein 
yang spesifik dan antigenik terhadap A. baumannii daripada protein membran luar 
(OMP) yang boleh digunakan untuk membangunkan ujian diagnostik yang cepat dan 
spesifik. Profil protein daripada strain ATCC and isolat klinikal A. baumanii telah 
didemonstrasi dengan menggunakan teknik SDS-PAGE dan profil protein yang 
terhasil daripada kedua-dua strain tersebut dibandingkan. Profil protein daripada 
isolat klinikal didapati mempunyai persamaan lebih kurang 90% dengan strain 
ATCC. Seterusnya, protein elektroforetogram tersebut diuji dengan analisis blot 
 xvii
Western yang ditindak balas dengan serum daripada pesakit yang dijangkiti dengan 
A. baumannii. Satu protein OMP yang antigenik dan juga spesifik berberat molekul 
34.4 kDa telah dapat dikenalpasti hadir pada kesemua isolat A. baumannii yang 
dikaji dan tidak bertindak balas silang dengan serum daripada pesakit yang dijangkiti 
dengan pathogen nosokomial lain atau kontrol normal yang diuji. Eksperimen 
tersebut diulang beberapa kali untuk mengesahkan keptusan tersebut.  
 
Kajian ini juga dijalankan untuk menilai kesan peningkatan suhu terhadap 
pengekspresan protein OMP. Profil protein pada suhu 41C menunjukkan sebilangan 
OMP diekspres dengan kuantiti lebih tinggi (17.3, 22.4 and 60.5 kDa), sementara 
sebahagian protein yang lain menunjukkan penurunan dalam kuantiti protein yang 
diekspresi.  Keputusan ini mengesyorkan bahawa peningkatan suhu badan semasa 
jangkitan A. baumannii mempengaruhi pengekspresan protein bakteria tersebut, 
kemungkinan sebagai mekanisma pertahanan terhadap suhu tinggi dan juga rintangan 
terhadap dadah/ubat bagi memastikan bakteria tersebut boleh hidup dan tumbuh 
dalam badan pesakit.  
 
Keputusan ujian ini juga menunjukkan bahawa protein 34.4 kDa tersebut hadir pada 
kedua-dua penyediaan OMP dan SAP daripada A. baumannii serta bukan sejenis 
glikoprotein. Antigen 34.4 kDa hadir dalam ke semua isolat klinikal yang diuji dan  
didapati ia diekspres dengan kuantiti lebih tinggi pada suhu  41C. Ini mencadangkan 
bahawa protein ini mempunyai peranan yang penting dalam mekanisma patogenisiti 
bakteria tersebut. Sehingga kini, tiada kajian yang dilaporkan mengenai protein yang 
spesifik terhadap A. baumannii. Keputusan kajian yang diperolehi adalah 
memberansangkan dengan penemuan protein 34.4 kDa yang spesifik terhadap A. 
 xviii
baumannii dan boleh digunakan sebagai biomarker dalam pembangunan ujian 
diagnostik yang lebih cepat dan lebih spesifik jika dibandingkan teknik ujian 
diagnostik yang digunapakai pada masa kini. Walau bagaimanapun, kajian lanjutan 
perlu dilakukan untuk mengukur tahap antibodi terhadap protein tersebut, sensitiviti 
dan spesifisiti dan tempoh masa antibodi terhadap protein tersebut dapat dikesan di 
dalam serum pesakit. 
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DEMONSTRATION OF ANTIGENIC AND SPECIFIC ANTIGENIC AND 
SPECIFIC OUTER MEMBRANE PROTEIN(S) (OMPs) OF Acinetobacter 
baumannii 
 
ABSTRACT 
 
Acinetobacter baumannii has been recognized as an emerging nosocomial pathogen and 
is very often multi-resistant to antibiotics.  It has also been identified as an important 
cause of morbidity and mortality in hospitals, especially among immunocompromised 
patients. Early diagnosis of infection caused by A. baumannii is the major strategy for 
limiting controlling the nosocomial infection caused by this pathogen. Current 
identification of this   of the bacteria is by conventional culture method and biochemical 
tests, which may takes about 2 to 7 days to produce results. Hence, there is a need for a 
new rapid, sensitive, specific and economical test that would allow for the rapid 
management of nosocomial A. baumannii infections. 
 
 
Development of a specific and sensitive diagnostic test requires a biomarker, which does 
not cross react with other bacteria and is specific only to A. baumannii. This formed the 
aim of this study; to detect the presence of a specific and antigenic biomarker for A. 
baumannii from the outer membrane proteins (OMPs), which can be used for the 
development of a rapid and specific diagnostic test.   Protein profiles of OMP lysates 
from the ATCC strain    (Belgium) and clinical isolates of A. baumannii (Department of 
Medical Microbiology and Parasitology, School of Medical Sciences, USM) were 
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obtained by applying  demonstrated using the technique of Sodium Dodecyl Sulfate-
Poly Acrylamide Gel Electrophoresis (SSDS-PAGE) and the protein profiles were 
compared. The protein profiles of the clinical isolates were 90% identical to that of the 
ATCC strain. Following this, the protein electrophoretograms were subjected to Western 
blot analysis using serum from patients infected with A. baumannii and non-A. 
baumannii. The Western blot analysis revealed a  34.4 kDa antigen which was 
immunogenic when probed IgA, IgM and IgG of A. baumannii sera but did not cross 
reacted with sera from other nosocomial infections and normal controls. This was 
confirmed by repeated testing. 
 
The 2 sera (AB 009 and AB 012) from A. baumannii infection showed 19 and 16 
positive bands respectively of which 4 bands were recognized by both the sera. These 4 
protein bands were checked for cross reactivity using sera from patients infected with 
Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli or normal 
controls. The three proteins other than the 34.4 kDa protein cross reacted with sera from 
other nosocomial infections or normal controls. The 34.4 kDa antigen did not show any 
cross reaction with sera from other nosocomial infections and normal controls 
suggesting that this protein was specific for A. baumannii. This was confirmed by 
repeated testing.  
 
Studies were also done to : 
(i) asses the effect of temperature (41oC-identical to the temperature in patients with 
fever during nososocomial infection) on the expression of the OMPs. (ii) determine the 
location of the protein by SDS-PAGE analysis of the OMPs, Surface associated proteins 
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(SAPs) and inner membrane proteins (IMPs) of A. baumannii in order to identify the 
location of the protein.  
 
The proteinOMPs profile expressed at 41oC showed a number offew proteins were over-
expressed  OMPs to be increased in expression (17.3, 22.4 and 60.5 kDa) while some 
proteins also showedwere down- regulated,ion suggesting that the higherelevated body  
temperature of the body during A. baumannii infection influences the expression of the 
bacterial proteins for survival of this bacterium., probably as a mechanism of survival at 
higher temperatures and also for resistance against drugs to ensure its survival and 
growth in the body.  
 
The 34.4 kDa antigen, was present in all the clinical isolates and hence can be 
considered as a specific biomarker with great potential as a diagnostic marker. However, 
the effect of temperature was not uniform in the clinical isolates studied showing 
increased expression of this protein in 60% of isolates and the down regulation or no 
effect in 40% of the clinical isolates. This suggests that this protein may not have a 
strong protective role to play and hence may not be suitable as a vaccine candidate.     
 
It was found thatFurther characterization of the 34.4 kDais protein demonstrated that it 
was associated with both OMPs and SAPs of A. baumannii and . is Besides this, the 
protein was also analysed for its glycosylation status using glycoprotein staining and 
also for the main constituents using trypsin digestion. Results showed that it was not a 
glycoprotein, its main constituents being protein. The 34.4 kDa antigen was present in 
all the clinical isolates of A. baumannii. The expression of this protein was enhanced in 
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most cases suggesting that this protein could also be related to the virulence of the 
bacteria. To date, no previous report is available with reference to this specific protein 
for A. baumannii.  
 
 
Overall, the results of this study has identified a unique protein expressed by the A. 
baumannii clinical isolates which is specific to A. baumannii and does not cross react 
with other bacterial species responsible for nosocomial infections. Western blot analysis 
showed the protein to be antigenic and induce antibodies. Chemical characterization 
showed that its main constituent is protein and is not glycosylated. 
 
The results are encouraging in that the 34.4 kDa protein identified is specific for A. 
baumannii and can be used as a biomarker for development of a diagnostic test which 
would be faster and more specific than the current techniques of diagnosis. However, 
further studies need to be done to measure the antibody level against this specific 
protein, the sensitivity and specificity of the protein and the retention time of the 
antibody detectable in the serum of the infected patients. Since routine culture methods 
to identify the bacterial infection are laborious, time consuming, relatively expensive 
and low sensitivity, the development of a more rapid and simplified diagnostic test of 
Acinetobacter infection is highly desirable. The test must be sensitive, specific, and easy 
to perform, cost effective and be able to detect the presence of A. baumannii directly 
from patients’ blood. As such the objective of the study was to determine the presence of 
a specific and antigenic outer membrane protein (OMPs) of A. baumannii, which can be 
used for the development of a rapid diagnostic test. Proteins profiles were obtained by 
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applying the techniques of sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blot analysis was done to detect the presence of IgM, IgA 
and IgG. All sera from patients infected with A. baumannii were collected from the 
Department of Medical Microbiology & Parasitology, School of Medical Sciences, 
USM. By the method of elimination, antigenic protein band with a molecular weight of 
34.4 kDa, which, was uniquely seen only by A. baumannii sera and do not cross react 
with other sera tested was identified. This protein was shown to be antigenic when 
probed with anti human IgM, IgA and IgG by using patients sera infected with A. 
baumannii. Moreover, it was found to be specific for A. baumannii  and did not cross 
react with other sera that causing nosocomial infections (Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Escherichia coli etc), most commonly found in hospital 
Universiti Sains Malaysia (HUSM). Study was also done to  determine the location of 
the protein as to whether it is present on outer membrane only or present in other 
membranes (surface or inner membrane). It was found that this band was exist in surface 
associated protein. Besides this, the protein was also analysed for its glycosylation status 
using glycoprotein staining and also for the main constituents using trypsin digestion. 
Results showed that it as not a glycoprotein, its main constituents were protein. To date, 
no previous report has been made regarding the protein. However, further studies --------
- 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.0  Introduction 
Acinetobacter baumannii is a Gram-negative, non-motile, obligate aerobic coccus 
coccobacilli that is commonly found in soil, water and sewage, and in healthcare settings 
(Baumann et al. 1968; Juni 1978Dijkshoorn et al., 2007; Perez et al., 2007; Shih et al., 
2008). Difficulties in containing, controlling and eliminating the spread of A. baumannii 
have are challenges faced by challenged clinicians and healthcare providers (Bergogne-
Berezin and Towner 1996; Bernards et al. 2004; Koulenti and Rello, 2006). A. 
baumannii has emerged as an important and problematic human pathogen as it is the 
causative agent of several types of infections including pneumonia, meningitis, 
septicaemia and urinary tract infections. Recently, a drug-resistant A. baumannii was 
responsible for an outbreak of bacteraemia in more than 240 American troops in Iraq 
(Centers for Disease Control and Prevention 2004; Abbott Davis et al., 2005; Scott et 
al., 2007), and there is significant concern of a major epidemic involving this organism. 
This versatile organism can utilize a variety of carbon sources and is able to grow in a 
wide range of temperatures (28-53oC) and pH conditions (Yavankar et al., 2007). La 
Scola and Raoult (2004) isolated A. baumannii from human body lice and speculated 
that the bacteria may utilize the arthropod host as a one means of transmission. This 
hardiness, combined with its intrinsic resistance to many antimicrobial agents, 
contributes to the organism’s fitness and has enabled it to thrive in hospital settings 
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worldwide. Mortality in patients suffering from A. baumannii infections can be as high 
as 75% (Chastre and Trouillet,  2000).  
Alarmingly, little is known about the virulence, antibiotic resistance, or persistent 
strategies of A. baumannii. The pathogenic determinants that have been reported thus far 
for A. baumannii include a novel pilus assembly system involved in biofilm formation 
(Tomaras et al. 2003), an outer membrane protein (Omp38) that causes apoptosis in 
human epithelial cells (Choi et al. 2005), and a polycistronic siderophore-mediated iron-
acquisition system conserved between A. baumannii and Vibrio anguillarum (Dorsey et 
al. 2003, 2004). This presumably comprises a small fraction of elements involved in A. 
baumannii pathogenesis, and thus, novel global approaches are essential to 
comprehensively understand the basic features of this organism in order to ultimately 
control the spread of A. baumannii infections and to develop effective counter measures 
against this harmful pathogen 
 
Alarmingly, little is known about the virulence, antibiotic resistance, or persistence 
strategies of A. baumannii. The pathogenic determinants that have been reported thus far 
for A. baumannii include a novel pilus assembly system involved in biofilm formation 
(Tomaras et al. 2003), an outer membrane protein (Omp38) that causes apoptosis in 
human epithelial cells (Choi et al. 2005), and a polycistronic siderophore-mediated iron-
acquisition system conserved between A. baumannii and Vibrio anguillarum (Dorsey et 
al. 2003, 2004). This presumably comprises a small fraction of elements involved in A. 
baumannii pathogenesis, and thus, novel global approaches are essential to 
comprehensively understand the basic features of this organism in order to ultimately 
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control the spread of A. baumannii infections and to develop effective countermeasures 
against this harmful pathogen.  
 
A. baumannii has been stealthily gaining ground as an agent of serious nosocomial and 
community-acquired infection. Historically, AAcinetobacter spp. have been associated 
with opportunistic infections that were rare and of modest severity; the last two decades 
have seen an increase in both the incidence and seriousness of A. baumannii infection, 
with the main targets being patients in intensive-care units. Although this organism 
appears to have a predilection for the most vulnerable patients, community-acquired 
A. baumannii infection is an increasing cause for concern (Chastre et al. 2000). The 
increase in A. baumannii infections has paralleled the alarming development of 
resistance it has demonstrated. The persistence of this organism in healthcare facilities, 
its inherent hardiness and its resistance to antibiotics results in it being a formidable 
emerging pathogen. 
 
1.1  History and significance of Acinetobacter baumannii infection 
1.1.1  Epidemiology 
A. baumannii Acinetobacter baumannii has emerged worldwide as an important 
nosocomial pathogen, causing outbreaks particularly in intensive care units, in wards 
with patients who have serious underlying illness (Dijkshoorn et al., 2007). It is 
responsible for 2% to -10% of all Gram-negative bacterial infections in intensive care 
units in Europe and the United States (Herve Richet and Pierre Edouard Fournier, 2006). 
Imipenem is among the drugs of choice for treatment of nosocomial infections due to 
multidrug-resistant (MDR) A. baumannii isolates. However, their efficacy is being 
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increasingly compromised by the emergence of carbapenem-hydrolyzing ß-lactamases 
of molecular Ambler class B (VIM, IMP) and class D (OXA-23, OXA-58) (Poirel et al., 
2005; Coelho et al., 2006; Zong et al., 2008). 
 
 
A. baumannii has emerged as a highly troublesome pathogen for many institutions 
globally. Multi-drug resistant A. baumannii A. baumanniiThe organism(MDRAB)  has 
always been inherently resistant to multiple antibiotics.  Multi-drug resistant A. 
baumannii is abbreviated as MDRAB. Imipenem is among the drugs of choice for 
treatment of nosocomial infections due to MDRAB strains. However, their efficacy is 
being increasingly compromised by the emergence of carbapenem-hydrolyzing ß-
lactamases of molecular Ambler class B (VIM, IMP) and class D (OXA-23, OXA-58) 
(Poirel et al., 2005; Coelho et al., 2006; Zong et al., 2008). As a consequence of its 
immense ability to acquire or up-regulate antibiotic drug resistance resistant 
determinants, it has justifiably been propelled to the forefront of scientific attention. 
Apart from its predilection for the seriously ill within intensive care units, A. baumannii 
has more recently caused a range of infectious syndromes in military personnel injured 
in the Iraq and Afghanistan conflicts  (described earlierScott et al., 2007). 
 
). 
 
In conclusion, Tthe available evidence suggests that A. baumannii is an important 
human pathogen that is gradually gaining more attention as a public health threat. It 
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causes a significant proportion of infections in specific patient populations, especially in 
critically-ill patients receiving care in the ICU setting (Zaragoza et al., 2003; Lee et al., 
2004; Longo et al., 2007). This situation, together with the fact that A. baumannii 
isolates have inherent and/or easily acquired mechanisms of resistance against many of 
the available antimicrobial agents, makes this pathogen one of the most significant 
microbial challenges of the current era. More scientific efforts and resources are urgently 
needed to further elucidate the epidemiological and infection control issues related to A. 
baumannii infections, and to investigate treatment options for patients with multidrug- 
or pandrug -resistant infections. 
 
 
1.1.2  Classification/tTaxonomy 
In 1980s, Acinetobacter was first considered as an emergence of nosocomial pathogens. 
Members of the genus Acinetobacter have a long story of taxonomic change. This 
confusion makes it difficult to interpret the older medical and scientific literature 
(Bergogne-Berezin and Towner, 1996). Bergey’s Manual of Systematic Bacteriology 
classified the genus Acinetobacter in the family Neisseriaceae, but this arrangement has 
never been formally approved by the taxonomiststhe taxonomists have never formally 
approved this arrangement. After that, taxonomic developments have resulted in the 
proposal that members of the genus should be classified in the new family 
Moraxellaceae . This genus, Acinetobacter, r which is now defined as Ggram negative 
(but sometimes difficult to destain) coccobacilli, with a DNA G and +C content of 39 to 
47 mol%, that are strictly aerobic, non-motile, catalasse- positive, and oxidase- negative 
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(Bergogne-Berezin and Towner, 1996). So far 17 named species have been recognized 
and 15 genomic species (gen.sp.) have been delineated by DNA–DNA hybridization, 
which do not yet have valid names (Dijkshoorn et al., 2007). 
 
 
 
1.1.3  Properties of Acinetobacter baumannii 
1.1.3.1 Physical characteristics 
Acinetobacter baumannii does not have fastidious growth requirements and is able to 
grow at various temperatures and pH conditions (Bergogne-Berezin et al., 1996). The 
versatile organism exploits a variety of both carbon and energy sources. These properties 
explain the ability of Acinetobacter species to persist in either moist or dry conditions in 
the hospital environment, thereby contributing to transmission (Smith et al., 2007). This 
hardiness, combined with its intrinsic resistance to many antimicrobial agents, 
contributes to the organism’s vfitness irulence and has enabled it to spread in the 
hospital setting (Abbo et al., 2005). Clinical isolates of A. baumannii are capable of 
activating N-acylhomoserine-lactone biosensors with maximal activity in the stationary 
growth phase (Joly-Guillou et al., 2005). Acinetobacters are renowned for their ability to 
survive in the environment in dry conditions for prolonged periods, and environmental 
contamination represents an important reservoir for their dissemination (Aygun G  et al., 
2002). Another interesting feature of the catabolic capacity of A. baumannii is its 
inability to catabolize glucose. Recent report showed that this deficiency in A. 
baumannii as is due to the absence of hexokinase, glucokinase, or any other comparable 
enzyme that can transfer phosphate onto glucose. Thus, the first step of glycolysis 
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cannot be completed (Smith et al., 20075). 
 
 
 
 
 
 
 
 
 
1.1.3.2 Growth and cultural characteristics 
Acinetobacter grows rapidly on 5% sheep blood and MacConkey agars. Characteristic of 
colonies on , 5% sheep blood agar producingare smooth, opaque colonies, in which 
some isolates are ß-haemolytic. Colonies on MacConkey agar are light lavender colour 
indicating but do not non- lactose fermenting colonies lactose.  
 
 
1.1.3.3 Biochemical characteristics 
Acinetobacter A. baumannii is a oxidase- negative, catalalase- positive and urease- 
positive bacterium. It shows no reaction with indole and methyl red. In the Triple Sugar 
Reaction Iron (TSI) agar, it shows alkaline slant and neutral butt and it does not produce 
gas (H2S). 
 
1.1.3.4 Physiology and Morphology 
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Members of the genus Acinetobacter are non-motile coccobacilli that are frequently 
confused with Neisseriae in Gram stained samples. They are generally encapsulated, 
oxidase negative, catalase positive, obligate aerobic and they do not ferment 
carbohydrates. Acinetobacter spp. are short, plump, Gram negative (but sometimes 
difficult to destain) rods, typically 1.0 to 1.5 μm by 1.5 to 2.5 µmm in size during the 
logarithmic phase of growth but often becoming more coccoid in the stationary phase 
(Bergogne-Berezin and Towner, 1996). 
 
1.2  Clinical significance of Acinetobacter baumannii 
Acinetobacter A. baumannii is an important nosocomial pathogen that has been 
implicated in various ranges of infections that mainly affect critically ill patients in 
ICUs. Hospital-acquired infections caused by A. baumannii includes bloodstream 
infections, ventilator-associated pneumonia, skin and soft-tissue infections, wound 
infections, respiratory and urinary-tract infections, endocarditis, secondary meningitis 
etcand other infections. (Joly-Guillou et al., 2005; Lee et al., 2006 ;  Dijkshoorn et al., 
2007; Lee et al., 2008). These infections are mainly attributed to A. baumannii, although 
gen.sp. 3 and gen.sp. 13TU have also been implicated (Dijkshoorn et al., 2007). 
Nosocomial infections that are caused by other Acinetobacter species, such as A. 
johnsonii, A. junii, A. lwoffii  etc.  are rare and are mainly restricted to catheter related 
bloodstream infections (Dotret Tega et al., 20076). These infections cause minimal 
mortality and their clinical course is usually benign, although life-threatening sepsis has 
been observed occasionally (Linde et al., 2002). The most frequent clinical 
manifestations of nosocomial A. baumannii infection are ventilator-associated 
pneumonia and bloodstream infection, both of which are associated with considerable 
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morbidity and mortality, which can be as high as 30% to -5260% (Seifert et al., 19956; 
Cisneros et al., 2002; Wisplinghoff et al., 2004).  
 
 
Recently, bacteraemia caused by A. baumannii is one of the infections with the highest 
mortality rate in hospitals (Joly-Guillou et al., 2005). A survey by the Health Protection 
Agency in England found that patients with Acinetobacter bacteraemia were generally 
aged > 50 years, that the majority of the patients were male, and that 5% of the patients 
were hospitalized in general wards and 54% were in ICUs (Wisplinghoff et al., 2000). 
Risk-factors have been defined in many studies, and are essentially the same as those 
identified for other opportunistic bacteria (Lee et al., 2004; Falagas et al., 2006; Baran et 
al., 2008; Shih et al., 2008; Baran et al., 2008). Another study reported that sepsis and ⁄ 
or septic shock in 19% of patients with bacteraemia were caused by A. baumannii 
(Valero et al., 2001). This observation also highlighted the true pathogenicity of A. 
baumannii strains, with a crude mortality rate of 42%.  
 
 
 
The infection rate of A. baumannii in Hospital USM (HUSM) intensive care unit 
werewas shown to be higher than the one reported (19%) from Hospital UKM (another 
teaching hospital in Malaysia) by Rozaidi et al., 2002. In our current study, we found 
that the prevalence of A. baumannii infection in Hospital Universiti Sains Malaysia 
(HUSM ) is varyingies from year to year, and the overall prevalence of Acinetobacter 
infection in intensive care units was 12.65%. In 2005, 2006, 2007 and 2008 (up-to June) 
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the prevalence rate was 18.92%, 29.89%, 26.42% and 26.01% respectively (dData 
collected from Infection Control Unit, HUSM). The prevalence of A. baumannii 
infection in intensive care units (gGeneral ICU, nNeurosurgical ICU and nNeonatal 
ICU) was higher compared to the general ward. The overall prevalence of Acinetobacter 
infection in intensive care units was 12.65%. 
 
1.2.1  Pathogenesis   
A recent study (Smith et al., 2007) has revealed that a large portion of the genome of A. 
baumannii consists of pathogenicity islands (PAIs). PAIs contain genes implicated in 
virulence, of which the largest appears to contain a type IV secretion apparatus. Type IV 
secretion systems have been shown to play an important role in other human pathogens, 
including Bordetella pertussis, Legionella  , pneumophila, Brucella spp. and 
Helicobacter pylori (Schmidt & Hensel, 2004). In the case of A. baumannii, this may be 
more important, as PAI genes, like other virulence genes, respond to environmental 
stimuli and thus may only be expressed under stressful conditions.  
 
Smith et al. (2007) also compared the genome sequence of A. baumannii with that of its 
closest sequenced relative, the nonpathogenicnon-pathogenic A. baylyi, using the 
Artemis Comparison Tool (ACT) to identify A. baumannii virulence genes. They found 
that the most interesting differences between these two organisms’ lies in the 28 PAIs 
identified in A. baumannii. Many of the drug-resistance and potential virulence factors 
found in the A. baumannii genome reside on these islands, indicating that a large number 
of them are important factor for the pathogenesis of A. baumannii. This presumably 
comprises a small fraction of elements involved in A. baumannii pathogenesis, and thus, 
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novel global approaches are essential to comprehensively understand the basic features 
of this organism in order to ultimately control the spread of A. baumannii infections and 
to develop effective counter-measures against this harmful pathogen. 
 
Clinical isolate of A. baumanni is able to survive on abiotic surfaces (plastic or glass 
surfaces) and produce biofilm, a property that is most likely to be associated with the 
capacity of this pathogen to survive in hospital environments and medical devices, and 
cause severe infections in compromised patients (Tomaras et al., 2003). Recently, there 
was another study performed in Korea that showed that A. baumannii has significant 
correlation with epithelial cell adherence because of the ability to form biofilm (Lee et 
al., 2008). This is because cells growing in biofilms are highly resistant to the 
components of the human immune system and to numerous types of antimicrobial 
agents. The studyy also revealed that A. baumannii isolates carrying blaPER-1 showed a 
significantly higher capacity for epithelial cell adherence and biofilm formation when 
compared with A. baumannii isolates without blaPER-1 (Lee et al., 2008, Loehfelm et 
al., 2008). 
 
 
Being a human pathogen, A. baumannii must be able to utilize host 
resources in order to survive. Iron is an important resource that is not readily available in 
the human host; rather, it is found complexed with iron binding molecules such as heme, 
lactoferrin, and transferrin. Bacteria survive and multiply under iron-limiting conditions, 
such as those found in natural and host environments, by expressing active systems that 
gather this essential micronutrient (Echenique et al., 2001). A study was also performed 
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to check the iron uptake components of clinical isolates of A. baumannii showed that 
most of the clinical isolates contains fatA-like gene. This gene which is potentially 
involved in iron acquisition, can be located in different genomic regions in for different 
A. baumannii isolates. and Ddisruption of the fatA-like gene indeed will impairs the iron 
acquisition phenotype of this strain, hence confirming its role in iron transport (Dorsey 
et al., 2003).  
The pathogenic determinants that have been reported so far for A. baumannii include a 
novel pilus assembly system involved in biofilm formation (Lee et al., 2008; Tomaras et 
al., 2003), an outer membrane protein (Omp38) that causes apoptosis in human 
epithelial cells (Choi et al., 2005), and a polycistronic siderophore-mediated iron-ac-
quisition system conserved between A. baumannii and Vibrio anguillarum (Dorsey et 
al., 2003, Dorsey et al., 2004). 
 
1.2.41.2.2  Virulence factors 
Although Acinetobacter baumannii are considered to be relatively low grade pathogens, 
certain characteristics of these organisms may enhance the virulence of strains involved 
in infections. These characteristics include: the presence of a polysaccharide capsule, 
formed by L-rahmnose, D-glucose, D-glucuronic acid and D-mannose, which probably 
render the surface of strains more hydrophilic, although hydrophobicity may be higher in 
isolated from catheters or tracheal devices (Joly-Guillou et al., 2005). The property of 
adhesion to human epithelial cells in the presence of fimbriae and/or capsular 
polysaccharides. The production of enzymes which may damage tissue lipids and the 
potentially toxic role of the lipopolysaccharide component of the cell wall and the 
presence of lipid A. 
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Nosocomial A. baumannii bacteraemia may cause severe clinical disease that is 
associated with a high mortality rate of up to 17% to -752% (Cisneros et al., 19962002). 
This opportunistic pathogen causes a wide variety of serious infections in humans, 
mostly in compromised patients. Recently, A. baumannii has emerged as an important 
pathogen among wounded soldiers, threatening civilian and military patients (Davis et 
al., 2005; Scott et al., 2007; Niu et al., 2008). This opportunistic pathogen expresses a 
myriad of factors that could play a role in human pathogenesis. Among these factors are 
the attachment to and persistence on solid surfaces, the acquisition of essential nutrients 
such as iron, the adhesion to epithelial cells and their subsequent killing by apoptosis, 
and the production and/or secretion of enzymes and toxic products that damage host 
tissues. However, very little is known about the molecular nature of most of these 
processes and factors and almost nothing has been shown with regard to their role in 
bacterial virulence and the pathogenesis of serious infectious diseases. Fortunately, some 
of these gaps can now be filled by testing appropriate isogenic derivatives in relevant 
animal models that mimic the infections in humans, particularly the outcome of deadly 
pneumonia. Such an approach should provide new and relevant information on the 
virulence traits of this normally underestimated bacterial human pathogen. 
 
A. baumannii infections probably involve numerous factors, including virulence 
determinants, which have yet to be investigated. A. baumannii began to spread rapidly 
among patients in intensive care units (ICUs) in the1980s. But studies on Acinetobacter 
virulence factors are still at an elementary stage. Non-specific adherence factors, such as 
fimbriae, which help adherence to human gastric epithelial cells via adhesions, have 
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been described in A. baumannii (Lee et al., 2006). It is known that, under iron-deficient 
conditions, bacterial growth can be accompanied by the production of receptors and 
iron-regulated catechol siderophores, which will, in turn, favour bacterial growth and the 
expression of virulence factors (Goel et al., 2001). 
 
 
Acinetobacter also can trigger gastritis including hypergastrinaemia and stimulation of 
cytokine release by the expression of virulence factors (Rathinavelu et al., 2003). 
AnOother neuropathological studies have demonstrated that amino -acid sequence 
homology exists between a bovine prion sequence (RPVDQ) and an enzyme produced 
by Acinetobacter, uridine diphosphate-N-acetylglucosamine- 1-carboxyvinyl transferase,  
which  also contains the RPVDQ sequence and could be potentially cross-reactive. As a 
consequence, an antibody response to the Acinetobacter sequence could influence the 
pathology of the disease (Wilson et al., 2004).  
 
Approximately 30% of Acinetobacter strains produce exopolysaccharide, which is a 
major virulence factor and is thought to protect bacteria from host defences resulting in 
cytotoxicity for phagocytic cells (Joly-Guillou et al., 2005). In experimental studies, 
exopolysaccharide-producing strains of Acinetobacter have been shown to be more 
pathogenic than non-exopolysaccharide-producing strains, especially in polymicrobial 
infections with other species of higher virulence. 
 
  Quorum-sensing is another widespread regulatory mechanism among A. 
baumannii which is required for the later stages of biofilm maturation. At present, the 
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only known determinants required for biofilm formation in A. baumannii are the csu-
ecoded chaperone-usher pilus assembly system (Tomaras et al., 2003) and the Bap 
protein (Loehfelm et al., 2008). Recently another study showed that the abaI-directed 
quorum-sensing pathway is required for the later stages of biofilm maturation (Niu et al., 
2008). Quorum-sensing might be a central mechanism for auto-induction of multiple 
virulence factors in an opportunistic pathogen such as A. baumannii, and this process 
should be studied for its clinical implications (Joly-Guillou et al., 2005). 
 
 
1.2.3  5  Risk factors 
Acinetobacter A. baumannii is an important cause of nosocomial infections in many 
hospitals, which is difficult to both control and treat because of its prolonged 
environmental survival and its ability to develop resistance to multiple antimicrobial 
agents (Bergogne-Berezin et al., 1996; Cisneros et al., 2005; Yu-ChenTseng et al., 
2007; Cisneros et al., 2005; Bergogne-Berezin et al., 1996).  A. baumannii appears to 
have a propensity for developing antimicrobial resistance extremely rapidly. Moreover, 
this resistance is multiple, causing serious therapeutic problems (Cisneros et al., 2002). 
Several studies were conducted to find the risk factors as bacteraemia caused by 
multidrug-resistant A. baumannii (MDRAB) leads to higher mortality and medical cost 
compared with non-MDRAB bacteraemia. Risk factors may vary between areas with 
endemic colonization and epidemic outbreaks of infection (Rello et al., 1999; Garcia-
Garmendia et al., 2001; Mu-JenShih et al., 2008). ; Garcia-Garmendia et al., 2001; Rello 
et al., 1999). From the previous studies of risk factors, it was found that longer duration 
of hospital stay until A. baumannii isolation, ICU admission, emergent surgical 
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operation, total parenteral nutrition, invasive procedures such as central venous catheter, 
endotracheal tube, urinary catheter, or nasogastric tube, previous administration of 
carbapenems and previous exposure to broad-spectrum antibiotics have been identified 
as risk factors for acquisition of A. baumannii  in numerous studies were significant risk 
factors for A. baumannii infections ( Garcia-Garmendia et al., 2001; Joly-Guillou et al., 
2005; Gulseren Baran et al., 2008; Joly-Guillou et al., 2005; Garcia-Garmendia et al., 
2001). 
 
The risk factors that predispose individuals to the acquisition of, and infection with,  A. 
baumannii are similar to those that have been identified for other MDR multi-drug 
resistant organisms. Risk factors that are specific for a particular setting have also been 
identified, such as the hydrotherapy that is used to treat burn patients and the pulsatile 
lavage treatment that is used for wound treatment (Maragakis et al., 2004; Wisplinghoff 
et al., 1999; Maragakis et al., 2004). The most frequent clinical manifestations of 
nosocomial A. baumannii infection are ventilator-associated pneumonia and bloodstream 
infection, both of which are associated with considerable morbidity and mortality, which 
can be as high as 52% (Seifert et al., 1995; Cisneros et al., 2002; Seifert et al., 1995). 
 
 
1.2.46  Prevalence   
The prevalence of nosocomial bloodstream infections due to Acinetobacter A. 
baumannii currently has become a public health problem in many countries ranges 
ranging from 2% to 10% of all gram-negative bacterial infections in Europe (Hanberger 
et al., 1999) and account for about 2.5% of them in the United States (Jones et al., 
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2004). 
The incidence of severe infection caused by Acinetobacter species has been increasing. 
For example, National Nosocomial Infection Survey data for US intensive care units 
indicate that Acinetobacter species caused 6.9% of hospital-acquired pneumonia in 
2003, compared with 1.4% in 1975. The rates of bloodstream infection, surgical site 
infection, and urinary tract infection have also increased during this period (from 1.8% 
to 2.4%, 0.5% to 2.1%, and 0.6% to 1.6%, respectively (Gaynes et al., 2005). 
 A. baumannii exhibits a remarkable ability to rapidly develop antibiotic resistance that 
led to multidrug resistance (MDR) within a few decades (Bergogne Berezin et al., 
1996). To date, some strains of A. baumannii have become resistant to almost all 
currently available antibacterial agents (Van Looveren et al., 2004), mostly through the 
acquisition of plasmids (Joshi et al., 2003), transposons (Smith et al., 2007), or integrons 
carrying clusters of genes encoding resistance to several antibiotic families (Segal et al., 
2003; Poirel et al., 2003) at once. 
 
 
 
 
1.2.71.2.5  Antimicrobial susceptibility and resistant mechanisms 
Acinetobacter.  baumannii is attracting much attention owing to the increase in 
antimicrobial resistance and occurrence of strains that are resistant to virtually all 
available drugs (Perez et al., 2007). This organism is generally intrinsically resistant to a 
number of commonly used antibiotics, including aminopenicillins, first and second 
generation cephalosporins and chloramphenicol (Vila et al., 1993; Seifert et al., 19953). 
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It also has a remarkable capacity to acquire mechanisms that confer resistance to broad-
spectrum-lactams, aminoglycosides, fluoroquinolones and tetracyclines1. A. baumannii 
exhibits a remarkable ability to rapidly develop antibiotic resistance that led to multidrug 
resistance within a few decades (Bergogne Berezin et al., 1996). To date, some strains of 
A. baumannii have become resistant to almost all currently available antibacterial agents 
(Looveren et al., 2004), mostly through the acquisition of plasmids (Joshi et al., 2003), 
transposons (Smith et al., 2007), or integrons carrying clusters of genes encoding 
resistance to several antibiotic families (Segal et al., 2003; Poirel et al., 2003). 
Numerous studies have suggested an upward trend in strains of A. baumannii that are 
resistant to these agents. However, because of the scarcity of large-scale surveillance 
studies from the 1970s to the 1990s and the difficulties in comparing local reports, such 
trends are difficult to quantify on a global level. Resistance rates can vary according to 
the country and the individual hospital, and depend on biological, epidemiological or 
methodical factors (Seifert Wisplinghoff et al., 20076). Recently, resistance to 
polymyxins and tigecycline has have also been described, which indicates that A. 
baumannii can cause infections that are fully refractory to the currently available 
antimicrobial drugs (Li et al., 2006; Peleg et al., 2007). 
 
 
 
The resistance of A. baumannii to antimicrobial agents is mediated by all of the major 
resistance mechanisms that are known to occur in bacteria, including modification of 
target sites, enzymatic inactivation, active efflux and decreased influx of drugs (Poirel et 
al., 2003). Betaß -lactamases are the most diverse group of enzymes that are associated 
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with resistance, and more than 50 different enzymes, or their allelic forms, have been 
identified so far in A. baumannii (Dijkshoorn et al., 2007). In a previous study , aac(6' )-
Ib and aac(6' )-Ih have been identified as the most prevalent plasmid-mediated aac(6' )-I 
genes among A. baumannii strains through which aminoglycoside resistance can be  
attributed to at least nine distinct modifying enzymes with different combinations in 
some strains (Doi et al., 2004). In Aanother study reported that resistance to 
tetracyclines has been associated with tet (A) and tet (B) genes that encode tetracycline-
specific efflux pumps (Huys et al., 2005). ISAba1 is was also thought to have a key role 
in some carbapenem-resistant strains by enhancing the expression of the intrinsic OXA-
51-like carbapenemases (Turton et al., 2006). Another chromosomal system that is 
typically found in A. baumannii is the AdeABC efflux system (Magnet et al., 2001). 
Reduced susceptibility to carbapenems has also been associated with the modification of 
penicillin-binding proteins and porins or with upregulationup regulation of the AdeABC 
efflux system, which might result in high-level carbapenem resistance in A. baumannii 
(Bou et al., 20001). There was  Aanother study conducted by Felipe Fernandez-Cuenca 
and colleagues in 2003 showed that production of ß-lactamases of pI 6.3 and 7.0 and 
reduced expression of PBP 2 (penicillin-binding protein bBiotype 2) are the most 
frequently observed mechanisms of resistance to carbapenems (.Fernandez-Cuenca et 
al., 2003) 
 
  
 
 
1.2.81.2.6  Treatment 
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Recently, according to the infectious disease society of America (IDSA), A. baumannii 
is considered as one of the three increasingly problematic Gram-negative pathogens 
(Talbot GH., 2008). MDRAB infections are difficult and costly to treat. A study at a 
public teaching hospital found that the mean total hospital cost of patients who acquired 
MDRAB was $USD 98,575 higher than that of control patients who had identical burn 
severity of illness indices (Wilson et al., 2004). 
 
The incidence of severe infection caused by Acinetobacter species has been increasing. 
For example, National Nosocomial Infection Survey data for US intensive care units 
indicate that Acinetobacter species caused 6.9% of cases of hospital-acquired pneumonia 
in 2003, compared with 1.4% in 1975.; Tthe rates of bloodstream infection, surgical site 
infection, and urinary tract infection have also increased during this period (from 1.8% 
to 2.4%, 0.5% to 2.1%, and 0.6% to 1.6%, respectively (Gaynes et al., 2005). 
 
Therapy Treatment of Acinetobacter infection havess been complicated by increasing 
resistance due to aminoglycoside-modifying enzymes, ESBLs, carbapenemases, or 
changes in outer-membrane proteins and penicillin-binding proteins (Gales Levin et al., 
20021). In some parts of the United States, many isolates are now resistant to all 
aminoglycosides, cephalosporins, and fluoroquinolones (Landman et al., 2002). The 
carbapenems and combinations of a ß-lactam with a ß-lactamase inhibitor, such as 
ampicillin-sulbactam, retain useful activity, but resistance rates are increasing (Quale et 
al., 2003). In a rRecent study (Talbot, 2008), data showeds that for the carbapenems, 
which  have been demonstrated to have the greatest inherent activity against A. 
baumannii, the frequency of resistance have increased by 30%, from 9%  to 39% (p < 
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0.01).. The rate of resistance to fluoroquinolones increased from 50% to 73%, and to ß-
lactams from 39% to 66%% (p < 0.01 for each comparison). These changes in the 
epidemiology and resistance rates of A. baumannii have led clinicians to adopt 
therapeutic options, such as colistimethate sodium (‘colistin’ , also known as polymixin 
E), the use of which had previously been abandoned in clinical use because of an 
unacceptably high rate of renal toxicity (Falagas et al., 2005; Li et al., 20065). 
 
Currently, several studies have tested the in vitro activity of tigecycline, a semi-synthetic 
tetracycline (glycylcycline) against A. baumannii and reported good bacteriostatic 
activity (Seifert Curcio et al., 20086). However, current evidence casts doubt on the role 
of tigecycline as a treatment for MDRAB A. baumannii  infection, with reports showing 
of high tigecycline resistance (Navon-Venezia et al., 2007; Peleg et al., 2007; Reid et 
al., 2007; Ruzin et al., 2007; Peleg et al., 2007; Navon-Venezia et al., 2007).  The 
ability of Acinetobacter to rapidly acquired resistance to this new glycylcycline 
antimicrobial is cause for concern and adds further stimulus for the discovery of newer 
antimicrobials with activities against this problematic organism (Peleg et al., 2007). 
Recently, there was a study performed in USA to check the activities of tigecycline in 
combination with other antimicrobials. But However, the safety and tolerability 
associated with the elevated dosages for tigecycline are were not known determined 
(Scheetz et al., 2007). Because, Sso far no clinical trial has been performed and the exact 
role of tigecycline in therapy of A. baumannii infection remains to be defined (Talbot, 
2008). 
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Bloodstream infections with A. baumannii are occurring with increasing frequency, 
resulting in significant morbidity and mortality ranges ranging from 8% to 43% (Scheetz 
et al., 2007). Therefore, clinicians must resort to empirical combination therapy, which 
has an unproven utility , andwhere therapeutic failures and relapses can beis anticipated. 
Recently, BAL 30376 (Basilea Pharmaceutica Ltd, Switzerland), a novel ß-lactum/ß-
lactamase inhibitor combination, represents an interesting potential approach to therapy 
of multidrug resistant A. baumannii MDRAB (Talbot, 2008). But However, clinical 
study is has not yet been doneconducted on this therapy. In conclusion, we can say as 
noted reported by the IDSA, “A. baumannii is a prime example of mismatch between 
unmet medical needs and the current antimicrobial research and development pipeline”. 
 
1.31.3  Rationale of the study 
Acinetobacter A. baumannii appears to have a propensity for developing antimicrobial 
resistance extremely rapidlyly (Cisneros et al., 2002). Moreover, resistance involvesd 
multiple drugs and causeds serious therapeutic problems. The reason that antibiotic 
resistance leads to adverse outcomes is presumably because of an increased likelihood 
that antibiotic therapy will be ineffective or suboptimal (Lee et al., 2007). A higher 
sepsis-related mortality rate among patients with multidrug resistant A. 
baumanniiMDRAB bacteraemia, compared with that for patients with non-–multidrug 
resistant A. baumanniiMDRAB bacteraemia is likely associated with a longer delay in 
the initiation of appropriate therapy. Several studies have described the relationship 
between receipt of appropriate therapy and a favorable outcome for the patients with 
nosocomial bloodstream infections (Ibrahim et al., 2000; Zaragoza et al., 2003). 
Nosocomial bacteraemia due to MDRAB multidrug resistant A. baumannii is associated 
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with increased in medical costs, prolonged hospitalization, and an increased in mortality 
rate.   
 
Major obstacles in controlling this pathogen are the high contagiousness of the disease 
and the eimmergenceemergence of multi-resistance characteristics to the commonly 
prescribed antibiotics. As developing antimicrobial resistance to multiple antibiotics 
causesing serious therapeutic problems,. So it is crucial to develop a rapid method for 
identifying the bacteria in order to limit and control outbreaks. Immediate identification 
of the pathogen in clinical samples is critical to ensure proper clinical treatment, 
management of the patient and for epidemiological investigations. Current laboratory 
diagnostic method used to diagnose Acinetobacter infection relied rely on the time-
consuming growth in culture media, followed by isolation, biochemical and serological 
identification. The relatively low sensitivity and the difficulty in performing the current 
diagnostic procedure have called for an alternative diagnostic method for the early 
identification of the bacteria. A rapid, simple and reliable diagnostic test is highly 
desired. One such method involves detection of specific antibodies in clinical specimens. 
There is a need for the development of next generation immunoassay technologies 
which provide a more rapid, sensitive and portable assays. The iImmunoc 
Chromatography tTest (ICT) technology, which is based on the membrane-based 
antibody assays, has been shown to be a potential tool for the diagnosis of pathogens 
(Smits et al., 2003; Lammie et al., 2004). The advantages of the 
immunochromatography ICT test over culture method are rapidity, simplicity, do not 
require expensive equipment, do not require cold chain for transportation, enhanced 
sensitivity and specificity for early diagnosis and the test can be performed at the point 
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of care. However, there is no report on diagnostic applications employing the 
immunochromatography concept that have been developed for diagnosis of A. 
baumannii infection. A rapid and reliable diagnostic assay would significantly improve 
effective management of the disease especially among young children and particularly in 
patients who are critically ill or immunocompromised. To control outbreaks of the 
infection caused by A. baumannii and to prevent further complications, it is often 
necessary to treat patients with specific antibodies antibiotics at the early stage. This is 
also very important to reduce the morbidity and mortality and the selection of 
appropriate antibiotics to control the nosocomial infection caused by A. baumannii. 
Current global diagnostic trend is moving towards rapid immunochromatography ICT 
platform, there is a need to strategically convert to this test to achieve a more rapid 
laboratory diagnosis. Thus, efforts to be taken to minimize the delay in the 
administration of appropriate antibiotic therapy are essential, as are techniques to 
facilitate the earlier identification of drug-resistant organisms like A. baumannii. 
 
1.4  Objective of the study 
Nosocomial bacteraemia due to multidrug resistant A. baumanniiMDRAB is associated 
with increased medical costs, prolonged hospitalization, and an increased in mortality 
rate. Thus, efforts to minimize the delay in the administration of appropriate antibiotic 
therapy are essential., as are techniques to facilitate the earlier identification of drug-
resistant organism like A. baumannii. The ability to produce indigenous test for A. 
baumannii that are novel, specific yet cost effective would now provide a huge impact 
on public health management not only in Malaysia but all over the world. Thus, the main 
aim of this study is to find outdemonstrate the presence of a specific protein 
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